Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00481195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00481195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2008
Enrollment
257 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i depression